Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Public ClinicalTrials.gov record NCT03374488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metastatic disease.
Study identification
- NCT ID
- NCT03374488
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 84 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 22, 2017 (Actual)
- Primary completion
- Jul 27, 2018 (Actual)
- Completion
- Jul 23, 2020 (Actual)
- Last update posted
- Aug 22, 2025
2017 – 2020
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers | Chandler | Arizona | 85224 | — |
| University of California Irvine Medical Center | Orange | California | 92868 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | — |
| UCLA Hematology Oncology Santa Monica | Santa Monica | California | 90404 | — |
| Smilow Cancer Center at Yale-New Haven | New Haven | Connecticut | 06510 | — |
| Northside Hospital, Inc. - GCS/Annex | Atlanta | Georgia | 30341 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Quincy Medical Group | Quincy | Illinois | 62301 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| NYU Clinical Cancer Center | New York | New York | 10016 | — |
| Oklahoma Cancer Specialists & Research Institute | Tulsa | Oklahoma | 74146 | — |
| Oregon Health & Science University | Portland | Oregon | 97210 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina-Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| University of Tennessee Medical Center Knoxville | Knoxville | Tennessee | 37920 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37203 | — |
| US Oncology and Research | Fort Worth | Texas | 76177 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| VCU Massey Cancer Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 111 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03374488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 22, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03374488 live on ClinicalTrials.gov.